Natixis Advisors, L.P. Arrowhead Pharmaceuticals, Inc. Transaction History

Natixis Advisors, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 27, 2023	BUY	$28.0 - $40.56 $73,192 - $106,023	2,614 Added 12.24%	23,967 $972,000
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $47,082 - $76,764	1,589 Added 8.04%	21,353 $706,000
Q2 2022 Aug 12, 2022	BUY	$27.79 - $50.61 $549,241 - $1 Million	19,764 New	19,764 $696,000
Q4 2019 Feb 10, 2020	SELL	$28.14 - $73.01 $285,930 - $741,854	-10,161 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$26.26 - $34.86 $266,827 - $354,212	10,161 New	10,161 $286,000

306

95.9M

523K

493K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.23B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.